On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
While at the University of Geneva, I focused on researching leukocyte migration and vascular biology in the context of inflammatory diseases and cancer. Our work led to the discovery and subsequent study of various adhesion molecules, including CD31, JAM-C, Olfml-3, and integrins, all of which play critical roles in these biological functions. As a result of our research, the university has filed several patents encompassing monoclonal antibodies (e.g., those that block JAM-C and Olfml-3) and small molecules that target CD31. Building upon this foundation, multiple start-up companies have been established. I aim to examine how innovation and project-oriented research are managed in our academic laboratory, start-up companies, and large pharmaceutical industries by drawing upon real-world examples.
